Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 6/20 | 0.44 |
| ▸ | ACACB | O00763 | 2/20 | 0.43 |
| ▸ | ACACA | Q13085 | 2/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405250 | 0.91 | EGLN1 (0.63) | EGLN1MAPK8PDE2AMAPK1ALDH1A1 | |
| SCHEMBL3435155 | 0.91 | EGLN1 (0.63) | EGLN1MAPK8PDE2AMAPK1ALDH1A1 | |
| SCHEMBL4535795 | 0.91 | EGLN1 (0.63) | EGLN1MAPK8PDE2AMAPK1ALDH1A1 | |
| SCHEMBL4525793 | 0.90 | EGLN1 (0.66) | EGLN1KCNH2ACACBPDE2A | |
| SCHEMBL14809346 | 0.88 | EGLN1 (0.56) | EGLN1MAPK8KCNH2PTGER4PDE2A | |
| SCHEMBL3409508 | 0.87 | EGLN1 (0.64) | EGLN1KCNH2PTGER4PDE2APTGER2 | |
| SCHEMBL3408585 | 0.87 | EGLN1 (0.64) | EGLN1KCNH2PTGER4PDE2APTGER2 | |
| SCHEMBL3409110 | 0.87 | EGLN1 (0.64) | EGLN1KCNH2PTGER4PDE2APTGER2 | |
| SCHEMBL3407323 | 0.87 | EGLN1 (0.54) | EGLN1KCNH2PDE2AMAPK1ALDH1A1 | |
| SCHEMBL3409543 | 0.87 | EGLN1 (0.54) | EGLN1KCNH2PDE2AMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257539-B1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2014-09-10 | — | — | EP | claimed |
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | claimed |
| EP-2257539-B1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2014-09-10 | — | — | EP | disclosed |
| EP-2257539-B1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2014-09-10 | — | — | EP | disclosed |
| US-8278304-B2 | Substituted 4-hydroxypyrimidine-5-carboxamides | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278304-B2 | Substituted 4-hydroxypyrimidine-5-carboxamides | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278304-B2 | Substituted 4-hydroxypyrimidine-5-carboxamides | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2257539-A1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | Merck Sharp & Dohme Corp. (US) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009117269-A1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | MERCK & CO., INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | HIF1AN, EGLN2, EGLN3 | EGLN1 5/4885MAPK8 3417/4885KCNH2 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.